March 2023
Dr Mathias brings a wealth of experience in innovation, contract development and manufacturing to Oxford Biomedica
Stuart Henderson to take on newly created position of Vice Chair and Dame Kay Davies to become Senior Independent Director
Oxford, UK – 20 February 2023: Oxford, UK – Oxford Biomedica (LSE:OXB), a leading gene and cell therapy group, today announces that Dr Frank Mathias will officially join Oxford Biomedica as Chief Executive Officer (CEO) and Board member on Monday, 27th March 2023. His appointment was previously announced on 22nd November 2022. Dr Frank Mathias joins Oxford Biomedica from Rentschler Biopharma SE (“Rentschler”) where he has been CEO since 2016. He successfully transformed Rentschler into a leading global, full-service CDMO and transformed the financials of the business including a three-fold increase in revenue, while also improving efficiencies and profitability at an even faster rate. Dr Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, said: “We are extremely excited about the imminent arrival of Frank as our new CEO. Frank brings a wealth of experience in innovation, contract development and manufacturing to Oxford Biomedica and I feel, with Frank’s new leadership, we are extremely well-positioned to deliver the growth and full potential of the company given our leading technology. As a viral vector leader, Oxford Biomedica is poised to build its position as a world-class, innovation-led CDMO delivering life-changing therapies to patients.”
Dr Frank Mathias, incoming Chief Executive Officer, said: “I look forward to joining Oxford Biomedica and leading the Company in its mission to deliver innovative services to biopharma customers, enabling them to discover and deliver therapies that transform patients’ lives. Oxford Biomedica has a clear vision for the future, and I believe it has great potential to become the leader in the viral vector CDMO market. I firmly believe in the Company’s strategy for growth and am excited to start working towards our goal to deliver products to patients as quickly as possible.”
In addition, Oxford Biomedica announces two changes to its Board, both of which will also take effect on 27th March 2023. Stuart Henderson will become Vice Chair, a newly created position which replaces the previously combined role of Deputy Chair and Senior Independent Director, the position Stuart has filled since June 2020. Professor Dame Kay Davies will assume the role of Senior Independent Director, following her appointment as a Non-Executive Director in March 2021. -Ends-
Taylor Boyd, VP, Head of IR – T: +1 (984) 268 8488 / E: ir@oxb.com
Sophia Bolhassan, VP, Corporate Affairs and IR – T: +44 (0) 7394 562 425 / E: ir@oxb.com
Consilium Strategic Communications:
Mary-Jane Elliott / Matthew Cole / Matthew Neal
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients. Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, and is working on programmes from pre-clinical to commercial stage across a range of therapeutic areas with global partners. Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a US based subsidiary AAV manufacturing and innovation business, based near Boston, US. Further information is available at www.oxb.com .

Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023

Lyon,  FRANCE
New York, Jan.  25, 2023  (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Large Molecule Drug Substance CDMO Market Size, Share & Industry Trends Analysis Report By Application, By Service, By End-user, By Regional Outlook and Forecast, 2022 - 2028" - https://www.reportlinker.com/p06412055/?utm_source=GNW
These are companies that assist customers in drug discovery via manufacturing abilities by providing services and, thus, also help the pharmaceutical industry. Large molecules are proteins that tend to have a therapeutic effect. These are highly complex, and most biologics are composed of approximately 1300 or more amino acids. These are prepared so that they resemble human proteins. The rise in molecule drug approvals, growing infectious disease prevalence, and increasing favorability for innovative therapeutics demand more CDMO setups for the rapid development and manufacturing of drugs. Therefore, CDMOs’ research, knowledge, and manufacturing abilities are highly necessary to proceed with drug development. As such, many CDMOs engage in integrating third-party ventures, which are also propelled by biotech and pharma companies’ assistance through financial and technological assets. Most customers also expect CDMOs to offer their expertise even after manufacturing, like in commercial launches. This is mainly because CDMO’s customer base has expanded beyond the big pharmaceutical companies to smaller biotech firms. Additionally, many smaller biotech companies focus extensively on evolving their drug pipelines without any manufacturing experience. Therefore, taking help from CDMOs in development and manufacturing operations also enables the early incorporation of smaller biotech firms’ operations. COVID-19 Impact Analysis
Some governments imposed regulations that resulted in the procurement of sufficient volumes of therapeutics and vaccines that were produced locally. However, production capacities were still not at their maximum because of supply chain and lockdown constraints. Disrupted supply chains interfered with the procurement of goods needed in the production processes, like the single-use plastic bags, which CDMOs use in the reactors. In addition, the lockdown constraints introduced a reduction in the workforce. These constraints resulted in a significant increase in the lead times, which increased up to four times. The delayed production and increased demand further helped in the growth of the CDMOs. Therefore, the pandemic positively impacted the large molecule drug substance CDMO market. Market Growth Factors
Increasing Research And Development Of Biologics And Biosimilar
Since the pandemic, numerous businesses have been making significant investments in the creation of biologics and biosimilar compounds. Presently, biologics such as peptides, proteins, and monoclonal antibodies in the discovery stage are making up almost half of the candidates intended to be used as therapeutics. Biopharmaceutical businesses are increasingly putting their resources into research and development, and as a result, many novel biologics are either being developed or are in the pipeline. Hence, all of these factors aid in the growth of the large molecule drug substance CDMO market. Growing Cardiovascular Diseases (CVD) And CVD-Induced Deaths
According to a paper published in the Journal of the American College of Cardiology that examined the total severity of cardiovascular disease (CVD) burden, the amount of people who die from (CVD) is steadily increasing. This number also includes one-third of all deaths globally in 2019. The statistics highlight the urgent need for nations to set up affordable public health initiatives that are affordable and focused on lowering heart disease risk through modifiable behaviors. Market Restraining Factors
Complex Analytical Characterization Of Biologics And Strict Parameters And Regulations
The characterization of large molecules is extremely challenging. Biopharmaceutical companies are needed to characterize in numerous ways, including stability, purity, and function. Large molecules routinely demand a combination of many low and high-resolution techniques to validate the particle’s structure efficiently. Additionally, numerous post-translational modifications (PTMs) are produced by large molecules during the recombinant synthesis method. Hence, the rise in R&D and investments in product development are boosting the growth and advancement of the large molecule drug substance CDMO market. Application Outlook
Based on application, the large molecule drug substance CDMO market is categorized into mammalian, microbial, and others. The microbial segment procured a considerable growth rate in the large molecule drug substance CDMO market in 2021. Microbial systems are mostly utilized in the production of recombinant proteins to be used in therapeutic processes. As most of the drugs available in the market are produced through recombinant technologies, they propel the growth of microbial systems. Service Outlook
On the basis of service, the large molecule drug substance CDMO market is divided into contract manufacturing and contract development. The contract manufacturing segment acquired the largest revenue share in the large molecule drug substance CDMO market in 2021. Contract manufacturing performs various functions like target screening and identification, functional informatics and target validation, preclinical development, and candidate optimization and lead identification. End-User Outlook
Based on end-user, the large molecule drug substance CDMO market is segmented into biotech companies, CRO, and others. The CRO segment witnessed a considerable growth rate in the large molecule drug substance CDMO market in 2021. The clinical research organization needs the CDMOs assistance with the laboratory, clinical, preclinical, and discovery services. In addition, the rising demand for treatments of various diseases and disorders has also increased the volume of research to be conducted. Regional Outlook
On the basis of region, the large molecule drug substance CDMO market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific segment garnered the maximum revenue share in the large molecule drug substance CDMO market in 2021. A skilled workforce, compliable regulations, and lower overall costs are the main factors that propel the outsourcing of large molecule drug substances to the CDMOs of this region. The presence of a considerable consumer base present in this region has increased the need for improved medicines and treatment techniques. The major strategies followed by the market participants are Partnerships. Based on the Analysis presented in the Cardinal matrix; Boehringer Ingelheim International GmbH is the forerunner in the Large Molecule Drug Substance CDMO Market. Companies such as FUJIFILM Diosynth Biotechnologies Texas LLC, WuXi Biologics (Cayman), Inc., Eurofins Scientific SE are some of the key innovators in Large Molecule Drug Substance CDMO Market. The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eurofins Scientific SE, WuXi Biologics (Cayman), Inc, Catalent, Inc., Boehringer Ingelheim International GmbH, FUJIFILM Diosynth Biotechnologies Texas LLC (Fujifilm Corporation), Samsung Biologics Co., Ltd. (Samsung Group), Rentschler Biopharma SE, AGC Biologics, Inc. (AGC, Inc.), Recipharm AB (EQT AB), and Siegfried Holding AG. Recent Strategies Deployed in Large Molecule Drug Substance CDMO Market
Partnerships, Collaborations and Agreements:
Oct-2022: WuXi partnered with Toregem BioPharma, a Japan-based biotechnology company, primarily into providing therapeutic agents meant for designing dental regenerative medicines. The partnership involves developing TRG035, an antibody meant for the treatment of congenital adentia. The partnership aligns with WuXi’s aim to help global partners innovate new biologics solutions for patients worldwide. Oct-2022: FUJIFILM Diosynth Biotechnologies collaborated with RoosterBio, a US-based biotechnology company, primarily into providing stem cell products. The collaboration involves GMP manufacturing of exosome and cell therapies. The collaboration allows FUJIFILM to offer comprehensive cell therapy CDMO services to its customers. Dec-2021: WuXi partnered with ImmuneOncia, a South-Korea based Biotechnology Company, primarily into providing immunotherapies intended for the treatment of different types of cancer. The partnership involves leveraging WuXi’s cell line development, bioassay development, cell culture development, and biologics manufacturing to develop bio specific antibodies. The antibody targets Programmed death-ligand 1 (PD-L1), and Cluster of Differentiation 47 (CD47). Sep-2021: Boehringer teamed up with Twist Bioscience, a US-based synthetic biology company. The collaboration involves combining Twist’s skill in generating potent, diverse therapeutic antibodies and Boehringer’s expertise in drug discovery and development, which would enhance Boehringer’s ability to better serve its clients and patients. Apr-2021: Samsung Biologics teams up with TG Therapeutics, a US-based biotechnology company. The collaboration involves expansion of contract manufacturing for TG Therapeutics’ ublituximab, an antigen meant for use in lymphoma, leukemia, and multiple sclerosis. This collaboration aligns with Samsung Biologics’ vision to better serve humanity by bringing required treatments to the patients. Jan-2021: Boehringer partnered with Google, a US-based global technology company. The partnership involves integrating Boehringer’s competence in computer-based drug design and silico modeling with Google’s expertise in algorithms and quantum computers to work on R & D. The partnership aims to advance R & D processes, thereby introducing more medical developments. Oct-2020: WuXi collaborated with AB2 Bio, a Switzerland-based drug development and discovery company. The collaboration involves advancing Commercial-Scale Manufacturing of Tadekinig alfa, an IL-18 binding protein meant for monogenic Hemophagocytic Lymphohistiocytosis (HLH). Based on the agreement, AB2 Bio would transfer commercial manufacturing of Tadekinig alfa to WuXi. Sep-2020: Samsung Biologics signed an agreement with AstraZeneca, a UK-based public company, primarily into marketing drugs for several diseases including, gastrointestinal, respiratory, cancer, etc. The agreement involves Samsung Biologics providing large-scale manufacturing of drug substances and drug products supporting AstraZeneca’s biologics therapeutics. The agreement aligns with Samsung Biologics’ purpose to support clients bring out innovative solutions. May-2020: Rentschler Biopharma collaborated with Genmab, a Denmark-based biotechnology company. The collaboration involves a business model that aligns with the expansion strategy of Rentschler Biopharma’s U.S. site in Milford, MA, and aims to manufacture and process the development of bispecific antibodies built on Genmab’s DuoBody® technology platform. Feb-2020: Catalent signed a contract with Zumutor Biologics, a US-based biotechnology company, primarily into providing NK cell therapeutics. The agreement involves manufacturing Zumutor’s ZM008 meant for solid tumor treatment. Acquisitions and Mergers:
Aug-2022: Catalent acquired Metrics Contract Services (Metrics), a US-based organization, primarily into providing contract development and manufacturing services for the medical sector. The acquisition advances Catalent’s ability to better serve its clients, particularly those clients with R & D pipelines having rare, orphan, diseases for oncology and other therapeutic areas. Apr-2022: Catalent took over a manufacturing facility in Oxfordshire from Vaccine Manufacturing and Innovation Centre UK Limited (VMIC Ltd.). The new facility enables Catalent to join forces with the biomedical science community, thereby furnishing opportunities to reshape innovation, and ideas into treatment for patients. Feb-2022: Recipharm took over GenIbet, a Portuguese company, primarily into providing CDMO services. The acquisition strengthens Recipharm’s plan to expand in the Biologics market, particularly in drug substance manufacturing of novel ATMPs. Feb-2022: Recipharm took over Arranta Bio, a US-based company, primarily into supporting the development of health therapies. This acquisition forms a keystone in Recipharm’s plan to furnish drug developers with CDM services. Moreover, the acquisition expands Recipharm’s presence in the US. Jan-2022: Samsung Biologics acquired the remaining share of Biogen in Samsung Bioepis, a Joint Venture between Biogen and Samsung Biologics. The acquisition would advance development in therapeutics R&D and biosimilars. Dec-2021: Eurofins acquired Genetic Lab, a Japanese company, primarily into pathological diagnostics services. This acquisition complements Eurofins’ global network of clinical diagnostic laboratories and further boosts Eurofins’ Asia expansion. Sep-2021: Boehringer took over Abexxa Biologics, a US-based biotechnology company. The acquisition strengthens Boehringer’s devotion towards the discovery of tumor-antigen, and Abexxa’s expertise in antigen discovery and antibody generation complements Boehringer’s current approach to enable immune-targeting of cancer cells. Aug-2021: AGC Biologics acquired a commercial facility in Longmont, Colorado, USA from Novartis Gene Therapies. The acquisition expands AGC’s manufacturing capacity supporting its global end-to-end Cell and Gene Therapy (C&GT) offerings and further expanding cell and gene therapy presence in the US. Feb-2020: Siegfried took over two manufacturing sites in Spain from Novartis. This acquisition expands Siegfried’s global manufacturing network and aligns with its corporate strategy EVOLVE. The two new manufacturing facilities complement Siegfried’s current operations in drug products. Geographical Expansions:
Nov-2022: WuXi opened a new manufacturing facility in Fengxian, Shanghai. The facility is a Contract Research, Development, and Manufacturing (CRDMO) center, which would provide end-to-end services including process development, drug product development, analytical development, clinical drug substance, etc. The CRDMO center would enhance manufacturing and development capacity and would support the development of new biologics programs. Oct-2022: WuXi expanded its manufacturing facilities network, by opening a new facility in Shijiazhuang, Hebei Province, China. The new facility is a Contract Research, Development and Manufacturing Organization (CRDMO) center, named MFG8. MFG8 aligns with the company’s foundation for commencing any project within 4 weeks and allows WuXi to better serve evolving needs for drug substance services. Oct-2022: Catalent expanded its geographical footprint by setting up a new facility in Kansas City, Missouri. The expansion includes setting up two new analytical development laboratories to fulfill evolving demands of assay development. Scope of the Study

The Global Large Molecule Drug Substance CDMO Market size is expected to reach $19.2 billion by 2028, rising at a market growth of 8.7% CAGR during the forecast period

Laupheim,  GERMANY
LAUPHEIM, Germany and MILFORD, Mass., Dec.  07, 2022  (GLOBE NEWSWIRE) -- Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, is celebrating its 150th anniversary this year, and the company continues to evolve and grow. Adjacent to its existing facility in Milford, MA, the company has undertaken the largest expansion in its long history. The state-of-the-art Rentschler Biopharma Manufacturing Center (RBMC) will add 22,000 square feet of manufacturing cleanroom space and house four new 2,000 L single-use bioreactors, in addition to being highly automated and leveraging industry 4.0 solutions. As the company grows in terms of capacity, technology, projects, and clients, it is also growing its highly trained workforce. Earlier this year, the company kicked off an exciting program with MassBioEd and Worcester Polytechnic Institute (WPI) to train people re-joining the workforce for stable, attractive biotech manufacturing opportunities. MassBioEd’s Life Sciences Apprenticeship Program is building talent pipelines for positions like Biomanufacturing Technicians, providing individuals with non-traditional training opportunities to enter careers in the life sciences. Rentschler Biopharma joined as one of the first employer partners for the expansion of the program into Central Massachusetts. The inaugural group of ten (10) apprentices has completed 16 weeks of training: Eight weeks involved a MassBio-led curriculum including basic academic coursework, as well as an introduction to business and to biotech. The additional eight weeks were spent at WPI Biomanufacturing Education and Training Center (BETC) to learn the fundamentals of biotech production, including both upstream and downstream processes. Five of the apprentices started at Rentschler Biopharma in September, and the remaining five at the end of November. Mark Caswell, Vice President, Site Head, Rentschler Biopharma, Inc., said: “Rentschler Biopharma has remained relevant throughout its history by creating value sustainably for our employees and clients. We focus on anticipating the needs of tomorrow with highly trained and experienced people. The workforce training program we have undertaken with WPI and MassBioEd is truly a win-win situation, enabling people from underrepresented communities to enter careers in the biotech space while supporting our need to bring in new talent.”
About Rentschler Biopharma SE
Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. The company offers process development and manufacturing of biopharmaceuticals as well as related consulting activities, including project management and regulatory support. Rentschler Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. In order to offer best-in-class formulation development along the biopharmaceutical value chain, the company has entered into a strategic alliance with Leukocare AG. Rentschler Biopharma is a family-owned company with about 1,200 employees, headquartered in Laupheim, Germany, with a second site in Milford, MA, USA. In Stevenage, UK, Rentschler Biopharma has launched a company dedicated to cell and gene therapies, Rentschler ATMP Ltd.
For further information, please visit http://www.rentschler-biopharma.com . Follow Rentschler Biopharma on LinkedIn and Facebook . Contact:

Rentschler implements innovative learning program in collaboration with MassBioEd and WPI

Undertakes the largest expansion in its history and establishes new apprenticeship program. 12.07.22
Rentschler Biopharma , a global contract development and manufacturing organization (CDMO) for biopharmaceuticals, is celebrating its 150th anniversary this year, and the company continues to evolve and grow. Facility Expansion
Adjacent to its existing facility in Milford, MA, the company has undertaken the largest expansion in its long history. The Rentschler Biopharma Manufacturing Center (RBMC) will add 22,000 square feet of manufacturing cleanroom space and house four new 2,000 L single-use bioreactors, in addition to being highly automated and leveraging industry 4.0 solutions. As the company grows in terms of capacity, technology, projects and clients, it is also growing its highly trained workforce. Training Program
Earlier this year, the company kicked off a new program with MassBioEd and Worcester Polytechnic Institute (WPI) to train people re-joining the workforce for stable, attractive biotech manufacturing opportunities. MassBioEd’s Life Sciences Apprenticeship Program is building talent pipelines for positions like Biomanufacturing Technicians, providing individuals with non-traditional training opportunities to enter careers in the life sciences. Rentschler Biopharma joined as one of the first employer partners for the expansion of the program into Central Massachusetts. The inaugural group of ten (10) apprentices has completed 16 weeks of training: Eight weeks involved a MassBio-led curriculum including basic academic coursework, as well as an introduction to business and to biotech. The additional eight weeks were spent at WPI Biomanufacturing Education and Training Center (BETC) to learn the fundamentals of biotech production, including both upstream and downstream processes. Five of the apprentices started at Rentschler Biopharma in September, and the remaining five at the end of November. Mark Caswell, vice president, site head, Rentschler Biopharma Inc., said: “Rentschler Biopharma has remained relevant throughout its history by creating value sustainably for our employees and clients. We focus on anticipating the needs of tomorrow with highly trained and experienced people. The workforce training program we have undertaken with WPI and MassBioEd is truly a win-win situation, enabling people from underrepresented communities to enter careers in the biotech space while supporting our need to bring in new talent.”
Related News

Rentschler Biopharma Celebrates 150th Anniversary

LEUKOCARE provides a next-generation formulation technology platform for the protection of biological compounds to allow the development of better products. The proprietary SPS technologies are provided to development projects in pharma and medtech. LEUKOCARE's SPS improves the stability and quality of biologics, like antibodies and vaccines in dry and liquid formulation, and protects proteins in combination devices.

LEUKOCARE

STEVENAGE , United Kingdom and LAUPHEIM , Germany , June 13 , 2022 -- Rentschler Biopharma , a leading global contract development and manufacturing organization , today provided an update on progress at Rentschler ATMP , the Company 's dedicated cell and gene therapy facility located in Stevenage , UK , including an important key hire .

Rentschler Biopharma adds highly experienced executive to team and provides update on progress at Rentschler ATMP

Vetter provides easy to setup and use online Suggestion Boxes for SME companies to get suggestions from their staff. Big organizations (British Airways saved $30 mn) & Small organizations (Alamo Colleges saved $74,600) who have adopted Suggestion Systems have reaped huge rewards. We want to reawaken companies to the fact that their employees are a goldmine of improvement suggestions. We bill monthly (SaaS), with plans ranging from $19-299 a month.

Vetter

In mid-2020 , Vetter and Rentschler Biopharma entered this strategic alliance intended to create long-term value that enables clients to bring their complex products to patients more easily and faster , through the coordination of their respective manufacturing services .

Rentschler Biopharma and Vetter Unveil Joint Visualization

Vetter spealizes in aseptic filling and packaging of medical compound in syringe systems, cartridges and vials.

Rentschler Biopharma and Vetter Unveil Xpert Alliance.
A Joint Visualization of the Successful Strategic Collaboration.

MediGene

Amgen

Servier

Rentschler Biopharma is a full-service CDMO that supports global clients through to market approval of their products. The company's clients include biotech companies and pharmaceutical companies.

Wells Fargo Success Story

Professional Services

Platform Overview

Rentschler Biopharma

Rentschler Biopharma’s Customers

Compete with Rentschler Biopharma?

Compete with Rentschler Biopharma?

Discover the right solution for your team